Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEE VLP vaccine
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VEE VLP vaccine is an investigational virus-like particle (VLP) vaccine designed to prevent infection with Venezuelan equine encephalitis virus (VEEV), an alphavirus that causes severe encephalitic disease in humans and equids and is considered a potential biological warfare agent.[2][3] The vaccine consists of noninfectious VLPs that display VEEV structural proteins (capsid and envelope glycoproteins) but lack viral genomic RNA, thereby mimicking the native virion to elicit neutralizing antibody and cellular immune responses while avoiding the risk of replication.[2][4][8] A monovalent VEE VLP study agent, corresponding to the VEE component of the NIAID trivalent alphaviral VLP vaccine, has been evaluated in a clinical trial in healthy adults to assess safety and immunogenicity for protection against VEEV exposure.[3] The platform is being developed primarily for prophylaxis against Venezuelan equine encephalitis in at‑risk or potentially exposed populations, leveraging the rapid and scalable production advantages of VLP-based vaccines.[1][5][8]
- Other names
- monovalent VEE VLP vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on VEE VLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEE VLP vaccine.